HighVista Strategies’s Dyne Therapeutics DYN Stock Holding History

HighVista Strategies’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.32M	Buy	182,929 +123,286	+207%	+$2.13M	0.92%	34
2025 Q4	$1.17M	Buy	+59,643	New	+$1.13M	0.3%	93
2025 Q3	–	Sell	-26,324	Closed	-$251K	–	157
2025 Q2	$251K	Sell	26,324 -52,096	-66%	-$574K	0.09%	141
2025 Q1	$820K	Hold	78,420	–	–	0.32%	116
2024 Q4	$1.85M	Buy	78,420 +12,938	+20%	+$383K	0.69%	47
2024 Q3	$2.35M	Buy	+65,482	New	+$2.61M	0.81%	37
2023 Q2	–	Sell	-102,431	Closed	-$1.18M	–	141
2023 Q1	$1.18M	Hold	102,431	–	–	0.96%	30
2022 Q4	$1.19M	Hold	102,431	–	–	0.7%	37
2022 Q3	$1.3M	Sell	102,431 -139,436	-58%	-$1.6M	0.74%	37
2022 Q2	$1.66M	Buy	241,867 +73,176	+43%	+$504K	1%	32
2022 Q1	$1.63M	Buy	+168,691	New	+$1.44M	1.03%	26
2021 Q1	–	Sell	-23,760	Closed	-$499K	–	131
2020 Q4	$499K	Buy	+23,760	New	+$470K	0.32%	67

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

HighVista Strategies's DYN Position: Q1 2026 in Review

HighVista Strategies increased its Dyne Therapeutics (DYN) stake by 207% in Q1 2026, buying an estimated $2.13M and bringing the position to 182,929 shares worth $3.32M. The position accounts for 0.92% of the portfolio, ranked #34.

HighVista Strategies first reported a position in DYN in Q4 2020 and has held it in 12 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

HighVista Strategies held 182,929 shares of Dyne Therapeutics worth $3.32M as of Q1 2026.
HighVista Strategies bought 123,286 Dyne Therapeutics shares in Q1 2026, an estimated $2.13M.
Dyne Therapeutics made up 0.92% of HighVista Strategies's portfolio in Q1 2026, its #34 holding.
HighVista Strategies first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 12 quarters since.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.